Mitochondrial Myopathy Clinical Trial
Verified date | December 2001 |
Source | Office of Rare Diseases (ORD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
OBJECTIVES:
I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial
myopathy.
Status | Completed |
Enrollment | 1 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Long standing ophthalmoparesis and fatiguable weakness of the limbs - Mild ataxia and no central nervous system involvement - History of mitochondrial DNA deletion and a measurable biochemical defect of the respiratory chain - Steady deterioration in skeletal muscle mass and power over 5 years --Prior/Concurrent Therapy-- - Previous participation in studies of muscle disease natural history (CRC Protocol 183A) |
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Center for Research Resources (NCRR) | University of Rochester |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02895789 -
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
|
||
Recruiting |
NCT05590468 -
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
|
Phase 2 | |
Recruiting |
NCT00457314 -
The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease
|
Phase 2 | |
Completed |
NCT02367014 -
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
|
Phase 1/Phase 2 | |
Completed |
NCT00004353 -
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
|
N/A |